Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Evolus, Inc. (EOLS : NSDQ)
 
 • Company Description   
Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.

Number of Employees: 332

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.56 Daily Weekly Monthly
20 Day Moving Average: 1,434,750 shares
Shares Outstanding: 64.82 (millions)
Market Capitalization: $425.22 (millions)
Beta: 0.97
52 Week High: $17.12
52 Week Low: $5.71
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 6.84% 4.04%
12 Week -2.53% -6.57%
Year To Date -40.58% -48.06%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
520 Newport Center Dr. Suite 1200
-
Newport Beach,CA 92660
USA		 ph: 949-284-4555
fax: -		 ir@evolus.com http://www.evolus.com
 
 • General Corporate Information   
Officers
David Moatazedi - President and Chief Executive Officer
Vikram Malik - Chairman
Sandra Beaver - Chief Financial Officer
Simone Blank - Director
David Gill - Director

Peer Information
Evolus, Inc. (BJCT)
Evolus, Inc. (CADMQ)
Evolus, Inc. (APNO)
Evolus, Inc. (UPDC)
Evolus, Inc. (IMTIQ)
Evolus, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 30052C107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/03/26
Share - Related Items
Shares Outstanding: 64.82
Most Recent Split Date: (:1)
Beta: 0.97
Market Capitalization: $425.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/03/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 1.49
EPS Growth
vs. Year Ago Period: 23.08%
vs. Previous Quarter: 33.33%
Sales Growth
vs. Year Ago Period: 12.90%
vs. Previous Quarter: -0.61%
ROE
09/30/25 - -
06/30/25 - -
03/31/25 - -759.04
ROA
09/30/25 - -23.47
06/30/25 - -24.63
03/31/25 - -20.14
Current Ratio
09/30/25 - 2.02
06/30/25 - 2.27
03/31/25 - 2.34
Quick Ratio
09/30/25 - 1.53
06/30/25 - 1.86
03/31/25 - 2.16
Operating Margin
09/30/25 - -18.34
06/30/25 - -20.03
03/31/25 - -16.62
Net Margin
09/30/25 - -20.49
06/30/25 - -22.31
03/31/25 - -20.40
Pre-Tax Margin
09/30/25 - -20.23
06/30/25 - -22.05
03/31/25 - -20.15
Book Value
09/30/25 - -0.44
06/30/25 - -0.29
03/31/25 - -0.10
Inventory Turnover
09/30/25 - 4.68
06/30/25 - 5.74
03/31/25 - 6.90
Debt-to-Equity
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Capital
09/30/25 - -
06/30/25 - -
03/31/25 - -
 

Powered by Zacks Investment Research ©